Development and validation of a preclinical food effect model

Area of Science:

• Pharmacokinetics
• Drug Development
• Preclinical Research

Background:

• Understanding drug-food interactions is crucial for safe and effective drug development.
• Existing preclinical models often fail to accurately predict human food effects.
• Early identification of food effects can prevent costly late-stage failures.

Purpose of the Study:

• To develop and validate a preclinical canine model for predicting human food effects.
• To assess the influence of different diets and meal compositions on drug pharmacokinetics in dogs.
• To evaluate the impact of pentagastrin pretreatment on drug absorption in the canine model.

Main Methods:

• Beagle dogs were utilized as the in vivo preclinical model.
• Compounds with known human food effect propensities were studied.
• Various dietary conditions, including high-fat dog food and different quantities of the human FDA meal, were tested.
• Pharmacokinetic parameters (Cmax, AUC) were measured in fed and fasted states, with and without pentagastrin pretreatment.

Main Results:

• High-fat dog food did not effectively predict human food effects.
• The quantity of the human FDA meal administered to dogs was critical for predicting the magnitude of food effect.
• Fed/fasted Cmax and AUC ratios using a 50-g aliquot of the FDA meal showed the closest agreement with human data.
• Pentagastrin pretreatment increased fasted AUC for weakly basic compounds but did not affect fed AUC.

Conclusions:

• A preclinical canine model using a 50-g aliquot of the human FDA meal and pentagastrin pretreatment can predict human food effects.
• This validated model aids in identifying drug-food interactions as potential liabilities during early drug discovery and development.
• The model supports informed decisions in advancing compounds from discovery to clinical trials.